Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) Other Operating Expenses (2016 - 2026)

Myriad Genetics has reported Other Operating Expenses over the past 17 years, most recently at $71.4 million for Q4 2025.

  • Quarterly Other Operating Expenses fell 23.8% to $71.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $600.2 million through Dec 2025, up 87.8% year-over-year, with the annual reading at $600.2 million for FY2025, 87.8% up from the prior year.
  • Other Operating Expenses was $71.4 million for Q4 2025 at Myriad Genetics, up from $71.0 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $388.6 million in Q2 2025 and troughed at $47.8 million in Q3 2021.
  • The 5-year median for Other Operating Expenses is $71.2 million (2025), against an average of $93.3 million.
  • Year-over-year, Other Operating Expenses crashed 37.62% in 2024 and then surged 360.43% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $107.8 million in 2021, then rose by 15.86% to $124.9 million in 2022, then decreased by 7.45% to $115.6 million in 2023, then fell by 18.94% to $93.7 million in 2024, then dropped by 23.8% to $71.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Operating Expenses are $71.4 million (Q4 2025), $71.0 million (Q3 2025), and $388.6 million (Q2 2025).